Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

siltuximab

- PMLiVE

Should We Care About Rare Diseases? By Alastair Kent

Alastair Kent, OBE, the Director of Genetic Alliance UK and chair of Rare Disease UK tells us why it’s so important to care about rare disease and why we should...

Say Communications

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

- PMLiVE

Searching for health

Janssen France’s Emmanuelle Quiles on finding ways to produce pharma innovations in a challenging environment

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

Research Partnership

- PMLiVE

emotive eye healthcare app scoops mobile learning award

The Eye Education app was produced for Johnson & Johnson Vision Care

- PMLiVE

2015’s ‘premium’ prices dissuaded J&J from acquisitions, says Gorsky

More M&A activity anticipated in 2016 and beyond

- PMLiVE

Pharma trio join with top universities for new drug search

AZ, GSK and J&J join forces with Imperial, University College and Cambridge

- PMLiVE

Baxalta agrees to $32bn Shire takeover

Deal will  create one of the industry's top rare disease firms

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

- PMLiVE

The world is our laboratory

Janssen's Thomas Stark on his company's approach to innovation, collaboration and research

- PMLiVE

Another lost decade for research?

What does the patent landscape look like for antibiotics, vaccines and orphan drugs?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links